

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Biosenta Inc. (the **Company**)  
1120 Finch Avenue West, Suite 503  
Toronto, Ontario M3J 3H7

**Item 2. Date of Material Change**

January 22, 2015

**Item 3. News Release**

The news release attached hereto as Schedule A announcing the material change described herein was released through Marketwired at Toronto, Ontario on January 22, 2015.

**Item 4. Summary of Material Change**

The Company announced that it has completed the construction and testing of its plant to manufacture Tri-Filler.

Tri-Filler is used to protect drywall, resins and plastics, paper and textiles from mould, fungi, bacteria and viruses. Tri-Filler is manufactured using advanced nano-encapsulation technology in a reactor. The Tri-Filler compound and the manufacturing process have been patented by Biosenta.

**Item 5. Full Description of Material Change**

5.1 Full Description of Material Change

Please see attached press release for a full description of the material change.

5.2 Disclosure for Restructuring Transactions

Not applicable.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

The following is the name and business telephone number of an executive officer of the Company who is knowledgeable about the material change and this report.

Dene Rogers, President and CEO  
Tel: 416-410-2019  
Email: dene@biosenta.com

**Item 9. Date of Report**

January 23, 2015

# BIOSENTA INC

January 22, 2015

**“Biosenta Inc. commissions new plant to manufacture “Tri-Filler”, a mould and microbe protecting compound for a broad range of industrial applications; testing with potential customers commenced in January”**

Biosenta Inc. (**Biosenta**) [(CSE: ZRO)] is pleased to announce that it has completed the construction and testing of its plant to manufacture Tri-Filler.

Tri-Filler is used to protect drywall, resins and plastics, paper and textiles from mould, fungi, bacteria and viruses. Tri-Filler is manufactured using advanced nano-encapsulation technology in a reactor. The Tri-Filler compound and the manufacturing process have been patented by Biosenta.

The plant was constructed over an eight month period with a total cost of less than \$1 million. The plant has a capacity of 2 tonnes per hour. The laboratory testing of the plant has been conducted using a world renowned institution which has verified the Tri-Filler compound is being manufactured per design specifications.

Mr. Dene Rogers, President and CEO of Biosenta said “We have achieved a major milestone in the development of our industrial business with the successful completion of the Tri-Filler reactor and plant. Our next milestone is to complete field tests of the Tri-Filler product with potential customers, in a variety of industries, who will test Tri-Filler in their manufacturing processes.”

## **About Biosenta Inc.**

Biosenta Inc. develops and manufactures a range of chemical compounds for household and industrial applications using advanced nanotechnology.

Biosenta’s household disinfectants and cleaners possess similar levels of efficacy as traditional disinfectants with significantly lower concentrations of active ingredients resulting in lower toxicity. These disinfectants and cleaners will kill 100% of potentially deadly mold, fungi, bacteria and viruses on contact and prevent re-growth. The disinfectants are very safe due to the very low toxicity.

The industrial product, Tri-Filler, is embedded to protect various materials, including drywall, plastics and resins, from microbe formation. These compounds remain active for decades and protect the drywalls of buildings, objects such as furniture, carpet and shoes which contain plastic or resin, from mold, fungi, bacteria and viruses.



Both the household and industrial products are environmentally safe and biodegradable.

**Disclaimer**

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

**For further information contact:**

Dene Rogers, President and CEO  
Biosenta Inc.  
1120 Finch Avenue West, Suite 503  
Ph: 416-410 2019  
Email: [dene@biosenta.com](mailto:dene@biosenta.com)